Induction of mucosal tolerance to Bet v 1, the major birch pollen allergen - A review

Allergy and Clinical Immunology International

Volumn 14, Issue 1, 2002, Pages 17-24

  Wiedermann, Ursula ^a   Kraft, Dietrich ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALLERGEN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN E; OVALBUMIN; POLLEN ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ASTHMA; BIRCH; CONTROLLED STUDY; DESENSITIZATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; PREVALENCE; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; REVIEW; TH1 CELL;

EID: 0036180324     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Linkage analysis of IL-4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations
2. Genetic linkage of T-cell receptor α/δ complex to specific IgE responses
3. Association between atopy and variants of the β-sub-units of the high affinity immunoglobulin E receptor
4. Basic and practical aspects of recombinant allergens
5. Prevalence of asthma and atopy in two areas of West and East Germany
6. Microflora-associated characteristics in faeces from allergic and non-allergic infants
7. Allergy and modern society: Does "Western life style" promote the development of allergies?
8. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
9. Two types of mouse helper T cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 cells
10. Regulation of the development of type 2 T-helper cells in allergy
11. The influence of exposure to house dust mite, cat, pollen and fungal allergens in the home to primary sensitization in asthma
12. Breast feeding as prophylaxis against atopic disease: A prospective follow-up study until 17 years old
13. Differences in clinical and immunological reactivity of patients allergic to grass pollen and to multiple-pollen species. II. Efficacy of a double blind placebo controlled, specific immunotherapy with standardized extracts
14. Usefulness of immunotherapy in patients with severe summer hay fewer incontrolled by anti-allergic drugs
15. + T lymphocytes and eosinophils in the basal mucosa and increases in the number of cells expressing messenger RNA for interferon γ
16. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen
17. Isolation and characterization of the major allergen of birch pollen (Betula verrucosa)
18. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa
19. Recombinant allergens for immunoblot diagnosis of tree pollen allergy
20. The gene coding for the major birch pollen allergen, Bet v 1, is highly homologous to a pea disease resistance response gene
21. Purification and characterization of recombinant Bet v 1, the major birch pollen allergen
22. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy
23. Secondary structure and tertiary fold of the birch pollen allergen Bet v 1 in solution
24. Identification of multiple T-cell epitopes on Bet v 1, the major birch pollen allergen, using specific T-cell clones and overlapping peptides
25. Nonallergic individuals recognize the same T-cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients
26. The immunological relationship of epitopes on major tree pollen allergens
27. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning
28. Dissection of immunoglobulin E and T-cell reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy
29. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments; Candidates for a novel form of specific immunotherapy
30. Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis
31. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy
32. Skin test evaluation of genetically engineered hypoallergenic derivates of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and the rBet v 1 trimer in a Swedish before the birch pollen season
33. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives
34. Oral tolerance and regulation of immunity to dietary antigens
35. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
36. The biological reactions of the vegetable proteins. 1. Anaphylaxis
37. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor
38. Nasal tolerance to experimental autoimmune myasthenia gravis: Tolerance reversal by nasal administration of minute amount of IFN-γ
39. Regulatory Th2-type T-cell lines against insulin and GAD peptides derived from orally and nasally treated NOD mice suppress diabetes
40. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells
41. Oral tolerance in disease
42. Peptide-induced-T-cell regulation of experimental autoimmune encephalomyelitis: A role for IL-10
43. Nasal tolerance induction as a potential means of immunotherapy for autoimmune disease: Implications for clinical medicine
44. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen
45. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells
46. Characterization of the specify and duration of T-cell tolerance to intranasally administered peptides in mice: A role of intramolecular epitope suppression
47. Induction of tolerance via the respiratory mucosa
48. + T cells
49. Peripheral deletion of antigen-reactive T cells in oral tolerance
50. Murine model of oral tolerance: Induction of Fas-mediated apoptosis by blockade of interleukin-12
51. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: Anergy in the absence of suppression
52. Dose-dependent induction of distinct anergic phenotypes: Multiple levels of T-cell anergy
53. Oral tolerance, an active immunological process mediated by multiple mechanisms
54. Mechanisms preventing allergen-induced airway hyperreactivity: Role of tolerance and immune deviation
55. CTLA-4 is required for the induction of high dose oral tolerance
56. Regulatory T-cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
57. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
58. + T cells: IL-4 and IFN-γ have opposite effects, while TGF-β positively regulates its own production
59. B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance
60. T regulatory cells 1 inhibit a Th2-specific response in vivo
61. + T cells
62. Gamma delta T cells as mediators of mucosal tolerance: The autoimmune diabetes model
63. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant epitope from the major birch pollen allergen Bet v 1
64. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: Cholera toxin induces a Th1-like immune response to Bet v 1, the major birch pollen allergen
65. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1
66. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
67. + T cell responses precedes the development of tolerance in vivo
68. + cells suppress experimental autoimmune uveitis
69. The mode of action of immunologic adjuvants
70. Towards selective elicitation of Th1 controlled vaccination responses: Vaccine application of bacterial surface layer proteins
71. The role of CpG oligonucleotides in DNA vaccines
72. CpG DNA as a Th1 trigger
73. Oligodeoxynucleotides containing CpG motifs modulate the allergic immune response of BALB/c mice to Bet v 1, the major birch pollen allergen
74. Immunostimulatory DNA and applications of the allergic disease
75. Gee whiz: CpG DNA allergy therapy!
76. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin
77. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues
78. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin
79. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
80. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV
81. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57B1/6 mice
82. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
83. Antibodies and antibody secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates
84. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
85. A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM 197) of diphteria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
86. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
87. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
88. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine
89. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
90. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy
91. Suppression of antigen-specific T and B cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy
92. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice
93. The kinetics of oral hyposensitization to a protein antigen are determined by immune status and the timing, dose and frequency of antigen administration
94. Kinetic analysis of oral tolerance: Memory lymphocytes are refractory to oral tolerance
95. Induction of oral tolerance in the primed immune system: Influence of antigen persistence and adjuvant form
96. Mucosal tolerance as therapy: Intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to suppression of allergic immune responses and airway inflammation in sensitized mice
97. Immunological consequences of intervention in established immune responses by feeding antigens
98. Suppression of an established DTH response to ovalbumin in mice by feeding antigen after immunization
99. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice